Do Kim – Piper Sandler

Piper Sandler

A Piper Sandler analyst with 14 tracked ratings across 13 distinct tickers has a 40% success rate on the captured sample, covering both sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

2 years ago

2024-02-22 00:00:00+00

Track record

Aggregated

40% success rate

Bullish: 0
Hold: 2
Bearish: 0

Aggregated

Not available

Bullish: 2
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
IONSIONIS PHARMACEUTICALS INC	2024-02-22	unknown	$63.00	Aggregated
VRTXVERTEX PHARMACEUTICALS, INC.	2023-02-08	hold	$296.00	Aggregated
GILDGILEAD SCIENCES, INC.	2023-02-03	unknown	$112.00	Aggregated
CDXS	2023-01-19	buy	$23.00	Aggregated
CDXSCODEXIS INC.	2023-01-19	unknown	$23.00	Aggregated
SDGRSCHRODINGER INC	2023-01-19	unknown	$87.00	Aggregated
TVTXTRAVERE THERAPEUTICS INC	2023-01-11	unknown	$42.00	Aggregated
RIGLRIGEL PHARMACEUTICALS	2022-08-17	hold	$2.00	Aggregated
REPLREPLIMUNE GROUP INC	2022-08-16	unknown	$43.00	Aggregated
ABCLABCELLERA BIOLOGICS INC	2022-07-26	unknown	$22.00	Aggregated
EXELEXELIXIS INC	2022-07-26	unknown	$32.00	Aggregated
CDXS	2022-07-15	buy	$22.00	Aggregated
SRRKSCHOLAR ROCK HOLDING CORP	2022-06-23	unknown	$19.00	Aggregated
AFMDAFFIMED N.V.	2022-03-31	unknown	$7.00	Aggregated

Tickers covered(13)

Ticker	Ratings	Last rating	Sources
IONSIONIS PHARMACEUTICALS INC	1	2024-02-22	Aggregated
VRTXVERTEX PHARMACEUTICALS, INC.	1	2023-02-08	Aggregated
GILDGILEAD SCIENCES, INC.	1	2023-02-03	Aggregated
CDXS	2	2023-01-19	Aggregated
CDXSCODEXIS INC.	1	2023-01-19	Aggregated
SDGRSCHRODINGER INC	1	2023-01-19	Aggregated
TVTXTRAVERE THERAPEUTICS INC	1	2023-01-11	Aggregated
RIGLRIGEL PHARMACEUTICALS	1	2022-08-17	Aggregated
REPLREPLIMUNE GROUP INC	1	2022-08-16	Aggregated
ABCLABCELLERA BIOLOGICS INC	1	2022-07-26	Aggregated
EXELEXELIXIS INC	1	2022-07-26	Aggregated
SRRKSCHOLAR ROCK HOLDING CORP	1	2022-06-23	Aggregated
AFMDAFFIMED N.V.	1	2022-03-31	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.